Mission

Every day, we strive to eliminate the worlds most

devastating infectious diseases.
Vision
We envision a world where people live free from the
threat of infectious disease.
About Seattle BioMed
Seattle BioMed is the largest, independent, non-prot
research institute in the U.S. focused solely on the worlds
most devastating infectious diseases. More than 330
strong, we are dedicated to reducing human suffering
and saving lives by converting knowledge into solutions.
Our research is the foundation for new vaccines, drugs
and diagnostics that will benet those who need our
help most: the 14 million who will otherwise die each
year from infectious diseases.
Disease Focus
Emerging & Neglected Diseases
African sleeping sickness
Amebiasis
Chagas disease
Leishmaniasis
Toxoplasmosis
Malaria
Tuberculosis
Viral Diseases
HIV/AIDS
Inuenza

Printed on recycled paper.
2013 Seattle Biomedical Research Institute.
307 Westlake Avenue North, Suite 500 Seattle, Washington 98109-5219 USA
Phone: 206.256.7200 Fax: 206.256.7229 - seattlebiomed.org
2012
Freedom from Infectious Disease
ANNUAL REPORT
Seattle Biomedical Research Institute is a 501(c)3 nonprot organization.
Federal tax ID #91-0961784.
Accelerating Progress Help us continue to accelerate.
Letter from our President
Growing up in apartheid South Africa, I was acutely aware of the
burden of disease in poor communities. It fostered in me an intense
desire to help end the scourge of infectious disease, a pursuit that
ultimately brought me here, to Seattle BioMed. Every day, every
one of our scientists focuses his or her passion and expertise on
overcoming diseases that take a staggering toll on human life and
national economies. We need vaccines, new drugs and diagnostics
to end the threat of HIV/AIDS, tuberculosis (TB), malaria and other
infectious diseases so prevalent in resource-poor countries.
As a strong believer in the power of technology to alleviate human
suffering, I have devoted my career to advancing technologies that
address major health problems of the developed world. Today, I am
excited to be leveraging this experience in a new direction.
As Chair of the Board of Seattle BioMed since September 2012, I work
with a passionate group of trustees who share the belief that technology
applied to infectious disease can transform global health. We serve on
the Board because we know that, in this institution, deadly diseases
including HIV, tuberculosis and malariahave the full attention of some
of the worlds top scientists.
Seattle BioMeds integration of systems
biology, immunology and infectious disease
research is spurring insights and innovations
that will accelerate the development of life-
saving interventions not only by us, but also
by research organizations around the world.
Our recently approved ve-year strategic plan aims to further accelerate
this progress by focusing on three broad areas where Seattle BioMed
intends to bring value: inuence by creating new scientic knowledge
that can be built upon, invent by partnering to develop practical and
effective interventions, and educate by training future generations of
scientic leaders and innovators.
We know that the development of life-saving interventions relies upon
insights into the nature of disease that only come through basic research.
Such insights provide launching pads for invention as Seattle BioMed
scientists test out the best ways to translate these research ndings into
strategies that can overcome barriers to disease prevention and treatment.
As an independent research institution, Seattle BioMed has the freedom
to pursue the best opportunities to advance scientic knowledge and
develop solutions to infectious diseases. This means we can take risks
that academic institutions or commercial enterprises often forego, but
risks that are still focused on tangible outcomes, such as vaccines for
HIV, TB or malaria.
Our unique independent position means we also need independent
support. Translational research that bridges the gap between bench
and bedsidethe invent focus of our new strategic planunfortunately
receives limited support from traditional funding sources. This funding
gap must be bridged if we are to truly accelerate progress.
Through Seattle BioMed, private individuals and organizations have the
opportunity to expedite scientic discovery and to advance basic research
past the milestones needed to deliver new life-saving products to the
eld in resource-poor countries. I invite you to join us in supporting
these critical efforts.
In just the past year, insights
from Seattle BioMed scientists
have revealed new approaches to
the development of vaccines and
drugs for HIV, TB, malaria and
other parasitic diseases. New
computational analyses have
helped dene when someone
infected with latent TB is at risk
of developing active disease.
A new TB gene interaction map
is beginning to reveal signaling
pathways that are involved with
latent TB becoming active, which
will lead lead to the identication
of drug targets. In the HIV eld,
new insights are revealing why
most HIV vaccines fail to elicit
broadly neutralizing antibodies,
and how different vaccine designs
affect the response of the innate
immune system, the bodys rst
line of defense against infection.
In malaria, researchers have
discovered how the parasite
commandeers liver cells, an event
that is critical for their initial growth
in humans. Seattle BioMed
researchers have also made strides in
elucidating the structures of proteins
from a variety of pathogens,
providing a valuable resource for
future development of drugs,
vaccines and diagnostic tools.
The 2012 Annual Report brings
you highlights of progress made
in the past year, and outlines
work ahead based on our recently
completed ve-year strategic plan
that maps out the approaches that
will guide both basic research and
its translation into interventions
that improve and save lives.
I thank you for your support
of our science this past year and
invite you to continue investing
in the discoveries generated at
Seattle BioMed. Together, we can
accelerate progress in the ght
against HIV/AIDS, TB, malaria,
and other infectious diseases.
New tools and new
thinking are needed,
and Seattle BioMed
generates both.
I know of no better place to be,
and no better time to be here.
I am honored to be the new
President of this institution and
to lead from the strong foundation
created by Dr. Ken Stuart as
we apply cutting-edge tools to
infectious disease research, and
partner to translate those
discoveries into interventions
that can save lives. While Seattle
is in our name, the focus of
our work is global and so are
our collaborations.
One of the tools we apply is
systems biology. By embracing
the complexity of biology, systems
approaches enable the rational
design of new vaccines and drugs.
Seattle BioMed has become the
worlds rst research institute to
undertake the full integration of
systems biology, infectious disease
research, and immunology under
one roof. In doing so, we have
thrown open the doors to
accelerated progress.
Letter from our Board Chair
COMING TOGETHER TO ACCELERATE PROGRESS FOR GLOBAL HEALTH
2 1
Alan Aderem, Ph.D.
President and Director
Trevor Moody
Chair, Board of Trustees
three-dimensional structures of over 560 proteins
from more than 40 bacterial, protozoan and viral
pathogenssignicantly surpassing their contract
goals and providing a valuable resource for the
development of drugs, vaccine and diagnostic
tools. This fall, SSGCIDs contract with the National
Institute of Allergy and Infectious Diseases was
renewed for another ve years, and SSGCID expects
to both determine the structures
of another 400 proteins and to
work with collaborators to
understand their particular
functions in causing disease.
Immune response Io T. Scientists
at Seattle BioMed have broadened
the understanding of how the body
responds to TB by identifying how
the bacterium activates cells that
suppress the immune response
necessary to ght off infection.
An effective vaccine will not only
need to stimulate a robust immune
response, but also keep these
suppressor cells in check.
InvenI. Seattle BioMed scientists test the best
ways to apply basic research ndings and partner to
develop them into practical strategies for disease
prevention and treatment.
HIV and T-ceIIs. Seattle BioMed researchers recently
discovered how a very small number of people are
able to control their HIV infection and keep the virus
in check. The key lies in the balance between two
different types of T-cells. Scientists are now applying
systems biology to understand the underlying
mechanisms, which may reveal a new drug target
for AIDS prevention.
Mapping T gene inIeracIions. Seattle BioMed
has embarked on a major project to map how TBs
200 control genes (transcription factors) determine
the activity of its other 3,800 genesincluding those
that control the bacterias latent state. Simultaneously,
researchers have identied a signaling pathway critical
to the bacterias exit from latency and entry into active
disease. Seattle BioMed has already begun collaborations
to develop drug-like molecules that inhibit this system. A
drug that prevents the transition from latent to active TB
would represent a giant step forward in the control of
this deadly scourge, given that one third of the worlds
population is latently infected with TB.
AcceIeraIing cures !or severe maIaria. Seattle
BioMed scientists, in collaboration with scientic
groups at the University of Copenhagen and the
University of Edinburgh, discovered how malaria
parasites are able to bind to brain blood vessels and
cause cerebral malariathe most lethal form of the
disease. Identifying the molecules that allow malaria
parasites to stick to the brain will accelerate the
development of treatments.
EducaIe. Seattle BioMed fosters a continuum
of training and engages with students at all levels
of learning, to inspire tomorrows biomedical
pioneers and increase the capacity of our partners
in resource-poor countries.
MOVING FASTER TO IMPACT GLOBAL HEALTH
Seattle BioMed is one of a handful of research
organizations around the world that are pioneering
the systems biology of infectious disease research.
Every day, the scientists at Seattle BioMed strive to
end the threat of infectious disease by inuencing
how we think about those diseases, inventing new
solutions, and educating the next generation of
scientists and our community.
Inuence. Insights into the nature of infections
and the bodys response to them are the source of
every new intervention against devastating diseases.
In ways large and small, research ndings in 2012
from Seattle BioMed are changing how we think
about infectious disease.
EnabIing ceII suicide Io bIock maIaria. Malaria
threatens over 40 percent of the global population,
sickens hundreds of millions and kills hundreds of
thousands of people a year, the majority of whom
are children and pregnant women in Africa. Yet, no
vaccine is available, and drug resistance is a growing
problem. Seattle BioMed scientists have identied
how malaria parasites manipulate liver cells, where
they live during the early stages of infection, to
ensure their growth and survival. Strikingly, the
changes caused by parasitic infection are similar
to the changes that occur when cells become
cancerous. This suggests that some cancer drugs
could be used to prevent malaria and minimize
the development of drug-resistant parasites.
eveaIing nev proIein sIrucIures. Over the last
ve and a half years, the Seattle Structural Genomics
Center for Infectious Disease (SSGCID), a large-scale
collaboration led by Seattle BioMed, has solved the
Seattle BioMed initiatives supported the scientic
education of over 1,100 trainees, including visiting
scientists, postdoctoral scientists, graduate students,
undergraduate interns, work-study students, high
school students, and teachers. Of these, more than
900 students were from Washington State high
schools that engaged with the on-site BioQuest
program. Thirty eight percent of BioQuest Academy
students this past summer were from backgrounds
underrepresented in the sciences.
The Seattle-India Joint Research Training Program on
Global Infectious Diseases hosted a two and a half
day workshop on tuberculosis in New Delhi with 24
trainees. Discussions and lectures covered a variety
of topics including drug discovery, immunology,
drug resistance, and research ethics. The program
also hosted two young Indian TB scientists to train
at Seattle BioMed. India is estimated to have over
three million cases of tuberculosis with 320,000
deaths in 2011. More than 64,000 of those cases
are estimated to have multiple drug resistance.
Opposite: More than 40% of the worlds population is
at risk for contracting malaria, and children are at the
highest risk. A child in Africa dies from malaria every
60 seconds.
Left: BioQuest Academy students spend two weeks
during the summer immersed in a real lab setting.
Seventy ve percent of graduates go on to earn a
degree in the sciences, and about 20% have come
back to work at Seattle BioMed.
Alexis Kaushansky, Ph.D., Stefan Kappe, Ph.D., and Joe Smith, Ph.D., are just three of the malaria researchers
at Seattle BioMed pioneering new ways to accelerate the development of drugs and vaccines.
4 3
INFLUENCE, INVENT AND EDUCATE TO IMPROVE LIVES
for preventative treatment long before symptoms
emerge. Furthermore, being able to identify which
latently infected individuals are likely to develop
disease allows them to be recruited for vaccine trials,
which can greatly reduce the cost of clinical trials,
allowing researchers to more effectively evaluate
vaccine candidates.
In 2013, scientists will conduct additional studies on
samples collected from throughout Africa to conrm
these results. They will also use molecular genetics to
examine the role of newly identied gene candidates
in controlling TB infection.
Detecting new targets for a
malaria vaccine
The malaria vaccine candidate most advanced in testing,
RTS,S, is built on a single parasite surface protein, and
has an efcacy rate of roughly 30 percent. To improve
on this, Seattle BioMed scientists collaborated with the
Institute for Systems Biology to discover new antigens
on the surface of the malaria parasite. These antigens
Biomedical researchers around the world have been working for decades
to develop vaccines that can prevent HIV/AIDS, tuberculosis (TB), and malaria.
But with no simple way of measuring in the blood whether a vaccine candidate
is producing the desired immune response, the process of vaccine development
is painfully slow, expensive, and riddled with obstacles.
At Seattle BioMed, the integration of infectious disease research, immunology
and systems biology is illuminating the path. New tools and new approaches
are accelerating vaccine development against all three diseases.
Systematically learning from
TBs tricks
Globally, someone falls ill from TB every four seconds,
and someone dies from TB every 20 seconds. Now, new
research by Seattle BioMed scientists and colleagues in
South Africa has identied early indicators of whether
someone latently infected with the bacteria will become
sick. The breakthrough came from a study that involved
6,000 adolescents in Cape Town, South Africa. The
study begins to address a particularly challenging trait
of TB: its ability to remain latent within the lungs of
an infected person, emerging suddenly from this
dormancy to cause the active and contagious form
of the disease.
Did you know?
South Africa is the epicenter of
the collision between HIV and TB,
representing one third of the worlds
cases of co-infection. As many as
70% of South Africas TB patients
are also HIV-positive. HIV lowers the
immune response needed to ght off
infections like TB, and the exceptionally
high rates of both HIV and latent TB
in South Africa create a perfect storm
for co-infection.
NEW TOOLS AND NEW THINKING
At the outset of the study, all of the young people
recruited were latently infected with TB, but none had
active disease. Knowing that some small percentage
of the youth were likely to progress to active TB, the
researchers collected blood samples every six months
for two years. By the end of that time, 35 of the
adolescents had progressed to active disease.
Using a systems approach, researchers then compared
the blood samples of teens that did and did not develop
active disease. Analyses revealed patterns of gene
expression that appeared in people who progressed to
disease up to 18 months before symptoms appeared.
These biological markers should enable early detection
of emerging disease in people with latent TB, allowing
Above: Seattle BioMed scientists used systems
approaches to generate the rst predicted genome-
wide regulatory network for M. tuberculosis: a
blueprint for the discovery of the most inuential
genes in the pathogen. The size and number of
lines connecting the turquoise dots represent the
inuence of the control genescritical information
for drug discovery.
Opposite: Collaboration is a cornerstone of research at
Seattle BioMed. Systems biologists and TB researchers
like (left to right) Christoph Grundner, Ph.D., Lynn
Amon, Ph.D., Smitha Shankar, M.S., Dan Zak, Ph.D.,
and David Sherman, Ph.D., are nding creative new
ways to blend their expertise and develop new tools.
6 5
(continued on p. 7)
COLLABORATORS
could serve as additional targets for a vaccine, boosting
its ability to protect against disease. Scientists are also
using computational analysis to learn more about
how the immune system responds to malaria and to
discover more potential vaccine targets. Together,
these studies could identify new vaccine candidates
to improve or possibly replace RTS,S.
Re-engineering vaccines
In a ve-year multi-institutional collaboration led by
Seattle BioMed, immunologists, virologists, structural
biologists and computational designers collectively
examined why so many candidate HIV/AIDS vaccines
have failed to elicit neutralizing antibodies against the
virus. The team discovered that previously tested vaccines
fail to activate the cells that produce such antibodies.
Scientists at Seattle BioMed have now designed
new vaccine candidates to specically activate those
cells. The vaccine has been successfully tested in the
laboratory and is ready for testing in model systems.
Meanwhile, Seattle BioMed scientists, in collaboration
with scientists at the National Institutes of Health,
have discovered how adding different components
to a vaccine can change the character of the innate
immune response that vaccine produces. Since the
innate immune system then orchestrates the adaptive
immune response, these insights will enable more
effective vaccine design.
Much of what we study at Seattle BioMed has
implications for more than one disease. Seattle
BioMed scientists are now applying new knowledge
about better vaccine design to both HIV/AIDS and TB.
Likewise, antibody work in HIV will be important for
TB and malaria. As Seattle BioMed scientists work
together more closely and bring the power of
systems biology to bear, the pace of discovery
will further accelerate.
Conclusion
Seattle BioMed research is proving the power and
potential of systems approaches. Today, Seattle
BioMed is one of the few places in the world that
are aggressively integrating systems biology and
immunology into its infectious disease research. We
could neither do this, nor produce the stream of results
seen in past years, without the help of our supporters.
We thank them and we invite you to join our cause.
Sustained support is needed to make the most of our
scientists discoveries. Only then can we fully maximize
the potential of systems approaches and rapidly
accelerate the development of life-saving interventions.
Together, we strive toward breakthroughs in the
treatment and prevention of infectious disease.
8 7
United States
Antigen Discovery, Inc.
AttoDx, Inc.
Baylor Research Institute
Benaroya Research Institute at Virginia Mason
Beth Israel Deaconess Medical Center
Carnegie Institution
Centers for Disease Control & Prevention
Cincinnati Childrens Hospital Medical Center
Clemson University
Dana-Farber Cancer Institute
Duke University
Emerald BioStructures, Inc.
Emory University
Fox Chase Cancer Center
Fred Hutchinson Cancer Research Center
Haborview Medical Center
Harvard University
Howard Hughes Medical Institute
Indiana University
Infectious Disease Research Institute
Institute for Systems Biology
Intellectual Ventures
J. Craig Venter Institute
Johns Hopkins University
Los Alamos National Laboratory
Mayo Clinic
National Institutes of Health
Naval Medical Research Center
New York University
Northern Illinois University
Northwestern University
Oregon Health and Sciences University
Pacic Biosciences
Pacic Northwest National Laboratory
PATH
Polyclinic
Princeton University
Public Health - Seattle & King County
Ra Pharmaceuticals, Inc.
Ragon Institute
Rhode Island Hospital
Rockefeller University
Sage Bionetworks
Seattle Childrens Hospital
Sequella, Inc.
St. Jude Childrens Research Hospital
Stanford University
Statistics Collaborative, Inc.
Texas A & M University
The Scripps Research Institute
Tulane University
U.S. Environmental Protection Agency
University of California, Berkeley
University of California, Irvine
University of California, San Diego
University of California, San Francisco
University of Georgia
University of Iowa
University of Maryland
University of Michigan
University of Missouri-Kansas City
University of North Carolina
University of Pennsylvania
University of Rochester
University of San Diego
University of South Florida
University of Texas Health Science Center at Tyler
University of Texas Southwestern Medical Center at Dallas
University of Virginia
University of Washington
Vanderbilt University
Walter Reed Army Institute of Research
Walter Reed Army National Military Medical Center
Washington State University
Washington University in St. Louis
Yale University
Yecuris Corporation
International
Australian National University, Australia
Barcelona Centre for International Health Research, Spain
Centro de Investigaciones Biolgicas, CSIC, Spain
Charit-Universittsmedizin Berlin, Germany
Christian de Duve Institute of Cellular Pathology, Belgium
Egerton University, Kenya
ETH-Zurich (Swiss Federal Institute of Technology Zurich), Switzerland
Foundation for Innovative New Diagnostics, Switzerland
Grifth University, Australia
The Hospital for Sick Children, Canada
Imperial College London, UK
Institut de Recherches Cliniques de Montral, Canada
Institut Pasteur, France
Institut Pasteur, Korea
Institute of Parasitology, ASCR, Czech Republic
Instituto de Parasitologa y Biomedicina Lpez - Neyra, CSIC, Spain
International AIDS Vaccine Initiative
International Centre for Diarrhoeal Disease Research, Bangladesh
International Centre for Genetic Engineering and Biotechnology, India
International Centre for Genetic Engineering and Biotechnology, Italy
Jawaharlal Nehru University, India
Kagawa University, Japan
K-RITH (KwaZulu-Natal Research Institute for Tuberculosis and HIV),
South Africa
Mahidol University, Thailand
McGill University, Canada
Medical College, Kolkata, India
Nanomics Biosystems Pty Ltd, Australia
National Center for Drug Screening, China
National Cheng Kung University, Taiwan
The Netherlands Cancer Institute, The Netherlands
Oxford University, UK
Shanghai Institute of Materia Medica, China
Southeast University, China
Sun Yat-sen University, China
TDR/World Health Organization
Technion, Israel
Third Military Medical University, China
TriTryp Genome Consortium
Universidad de Antioquia, Colombia
Universidad del Valle, Colombia
Universidade Federal de So Paulo, Brazil
Universidade Federal de Viosa, Brazil
Universidade Federal do Piau, Brazil
Universit Laval, Canada
University of Alberta, Canada
University of British Columbia, Canada
University of Cambridge, UK
University of Cape Town, South Africa
University of Copenhagen and Rigshospitalet, Denmark
University of Dundee, UK
University of Edinburgh, UK
University of Erlangen-Nurnberg, Germany
University of Glasgow, UK
University of Lisbon, Portugal
University of Nairobi, Kenya
University of Queensland, Australia
University of the Witwatersrand, South Africa
University of Toronto, Canada
University of Waikato, New Zealand
Vrije Universiteit, The Netherlands
Walter and Eliza Hall Institute of Medical Research, Australia
Wellcome Trust Sanger Institute, UK
Systems biologist John Aitchison, Ph.D. (center) and HIV researchers Leo Stamatatos, Ph.D. (left) and
Don Sodora, Ph.D., are some of the researchers making strides towards a vaccine that activates the
types of immune cells best equipped to ght off HIV.
Of the 1.8 million deaths from HIV/AIDS per year
worldwide, 1.2 million are in Africa. Thirty four million
people globally are living with HIV.
SEATTLE BIOMED LEADERS
This is a publication of Seattle BioMeds
Communications Department.

Photo credits: Kyle Minch, p. 6, Alan Aderem,
p. 6 sidebar.
10 9
National Institute of Dental and
Craniofacial Research
National Institute of Diabetes and Digestive
and Kidney Diseases
National Institute of General Medical Sciences
PATH
Paul G. Allen Family Foundation
American Lung Association
Bill & Melinda Gates Foundation
Burroughs Wellcome Fund
Foundation for the National Institutes of Health
Implicit Bioscience Ltd.
Medicines for Malaria Venture
Faculty
Alan Aderem, Ph.D.
President & Director
John Aitchison, Ph.D.
Professor & Director of
Integrative Biology
Nick Crispe, M.D., Ph.D.
Professor
Malcolm Gardner, Ph.D.
Professor
Christoph Grundner, Ph.D.
Assistant Professor
Helen Horton, Ph.D.
Associate Professor
Stefan Kappe, Ph.D.
Professor & Program Director
Peter Myler, Ph.D.
Professor
Marilyn Parsons, Ph.D.
Professor, Program Director &
Director of Professional
Development
David Sherman, Ph.D.
Professor & Program Director
Joseph Smith, Ph.D.
Associate Professor
Donald Sodora, Ph.D.
Associate Professor
Leo Stamatatos, Ph.D.
Professor & Program Director
Ken Stuart, Ph.D.
Professor, Founder &
President Emeritus
Kevin Urdahl, M.D., Ph.D.
Assistant Professor
Ruobing Wang, M.D., Ph.D.
Associate Professor
Principal Scientists
Andrew Oleinikov, Ph.D.
Noah Sather, Ph.D.
Daniel Zak, Ph.D.
Senior Scientists
Lynn Amon, Ph.D.
Peter Askovich, M.D., Ph.D.
Jason Carnes, Ph.D.
Amy DeRocher, Ph.D.
Alan Diercks, Ph.D.
Mark Gilchrist, Ph.D.
Elizabeth Gold, M.D.
Ihn Kyung Jang, Ph.D
Heather Jaspan, M.D., Ph.D.
Bryan Jensen, Ph.D.
Kathleen Kennedy, Ph.D.
Vladimir Litvak, Ph.D.
Sebastian Mikolajczak, Ph.D.
Brian Oliver, Ph.D.
Stephen Ramsey, Ph.D.
Tige Rustad, Ph.D.
Ramsey Saleem, Ph.D.
Frank Schmitz, M.D., Ph.D.
Shahin Shaani, Ph.D.
Ashley Vaughan, Ph.D.
Clinical Trials
Jim Kublin, M.D., Ph.D.
Medical Director
Sara Healy, M.D.
Clinical Trial Investigator
Angela Talley, M.D.
Lead Trials Investigator
Afliate Faculty
Jerry Cangelosi, Ph.D.
Professor
University of Washington
Peter Doherty, MVSc, Ph.D.
Nobel Laureate
University of Melbourne
Rentala Madhubala, Ph.D.
Director of Advanced
Instrumentation Research Facility
(AIRF) Jawaharlal Nehru
University, New Delhi
Rob Moritz, Ph.D
Director of Proteomics Facility &
Associate Professor
Institute for Systems Biology
Achim Schnaufer, Ph.D.
Research Group Leader &
Medical Research Council (MRC)
Fellow
University of Edinburgh, UK
Management
Alan Aderem, Ph.D.
President & Director
Tom Blackwell
Director, Information Technology
Karen Blchlinger, J.D., Ph.D.
General Counsel
Susan Brown
Vice President, Institutional
Advancement
Louie Coffman
Senior Vice President, Strategy &
Business Development
Randy Hassler
Chief Operating Ofcer
Drew House
Senior Director, Finance
Kent Irwin
Director, Operations & Facilities
Eileen Murphy
Director, Program Management
Jeanine Willis
Director, Human Resources
BioQuest
Theresa Britschgi
Director, BioQuest
Council of
Scientic Advisors
Ra Ahmed, Ph.D.
Director, Emory Vaccine Center
Clifton E. Barry, III, Ph.D.
Senior Investigator, Chief,
Tuberculosis Research Section,
NIAID, NIH
Samuel I. Miller Ph.D.,
Professor of Medicine,
Microbiology, Immunology
and Genome Sciences,
University of Washington.
Michel C. Nussenzweig, M.D., Ph.D.
Sherman Fairchild Professor,
The Rockefeller University
Investigator, HHMI Laboratory
of Molecular Immunology
Jeffrey V. Ravetch, M.D., Ph.D.
Theresa and Eugene Lang
Professor, The Rockefeller
University; Head of the Leonard
Wagner Laboratory of Molecular
Genetics and Immunology
Bennett (Ben) M. Shapiro, M.D.,
Chair
Director of Research, Retired,
Merck Research Laboratories
John W. Shiver, Ph.D.
Vice President,
Worldwide Basic Research
Franchise Head, Vaccines,
Merck Research Laboratories
Mike Tyers, Ph.D.
Professor, Institute for Research
in Cancer and Immunology,
University of Montreal
Canada Research Chair in
Systems and Synthetic Biology
Thomas E. Wellems, M.D., Ph.D.,
Chief, Laboratory of Malaria
and Vector Research
NIAID, NIH
National Institutes of Health:
Eunice Kennedy Shriver National Institute of
Child Health and Human Development
Fogarty International Center
National Center for Research Resources
National Heart, Lung, and Blood Institute
National Institute of Allergy and Infectious Diseases
Sclavo Vaccine Association
Silver Family Foundation
United States Department of Defense Telemedicine
& Advanced Technology Research Center
United States-Israel Binational Science Foundation
Alan Alhadeff
Margaret Allen, M.D.
Ellsworth Alvord, Jr., M.D.
Mark Benjamin, Sc.D.
J. Paul Blake
Carol Bryan
Vince Bryan
Robert Bunting
Alice Burgess
John Creighton, Esq.
Andrew Dale
James Davie
Nancy Duncan
Bruce Easter
Janet Lane Eaton
Marlyn Friedlander
Steve Gillis, Ph.D.
Harris Hoffman
James A. Johnson
John King
Alvin Kwiram, Ph.D
Carol Lewis
Jilan Liu, M.D., M.H.A.
Katherine M. Lombardo
Emeritus Board
Gary McGlocklin
Peter Miller, J.D.
Susan Morgensztern
Peggy Morrow
Thomas ORourke
Judy Pigott
Gloria Pfeif
Erick Rabins
Thomas Ranken
Chuck Robertson
Gilbert Scherer
Michael D. Stull
Ezra Teshome
Usha Varanasi, Ph.D.
Tom Waldron
Rick Weller, M.D., D.T.M. & H.
Michelle A. Williams, Sc.D.
Mary Williamson
James Woods, Ph.D.
Jeffrey Wortley
Louis Yaseen
Updated 1/2013
FUNDERS
Fiscal year ending June 30, 2012
SELECT FI NANCI AL DATA
12 11
BOARD OF TRUSTEES
Dean Allen
Chief Executive Ofcer
McKinstry
Rosemary Barker Aragon
Executive Director
Pacic Hospital Preservation &
Development Authority
Mark Ashida*^
Vice Chair, Business Development Committee Chair
Chief Executive Ofcer
Symform
Richard Bear
Chief Financial Ofcer
CRH Medical Corporation
Jane A. Biddle, Ph.D.
Technology Transfer Consultant
Gregg Blodgett*^
Treasurer, Finance & Audit Committee Chair
Director, Chief Financial Ofcer
Booyami, Inc.
Maud Daudon*
Board Operations & Governance
Committee Co-Chair
President & CEO
Seattle Metropolitan Chamber of Commerce
Jane Hedreen*
Advancement Committee Co-Chair
Owner
Flora & Henri
Darryl Johnson*^
Secretary
Former US Ambassador to Thailand & Lithuania
Kevin F. Kelly, J.D.
Business Consultant, Drug and
Vaccine Collaborations
Retired Partner, Cooley LLP
Alan Levy, Ph.D.
Venture Partner, Medical Devices
Frazier Healthcare Ventures
Neil McDonnell, PharmD
Senior Vice President
Cardiovascular & Metabolic Diseases
Therapeutic Area
Takeda Pharmaceuticals
Terrence R. Meersman
Vice President, Programs
Margaret A. Cargill Foundation
Trevor Moody*^
Chair
President
TM Strategic Advisors LLC
Todd Patrick*
Immediate Past Chair
President & CEO
C3-Jian, Inc.
Christopher H. Porter, Ph.D.
President
Medical Genesis
Alexandre Portet
Deputy Director, Strategy Planning
& Management
Bill & Melinda Gates Foundation
Kris Richey Curtis*
Advancement Committee Co-Chair
Vice President
Kinzer Real Estate Services
David R. Stewart, J.D.
Executive Vice President & General Counsel
Vulcan, Inc.
Ken Stuart, Ph.D.
President Emeritus & Founder
Seattle BioMed
Moya Vazquez*
Board Operations & Governance
Committee Co-Chair
Community Volunteer
Bryan White
Managing Director & Chief Investment Ofcer
BlackRock Alternative Advisors
Melissa Yeager
Chief Operating Ofcer
Cardeas Pharma
^ Ofcer
* Member of Executive Board
Updated 1/2013
*Includes one-time contribution to support
scientic expansion and leadership

Audited statements available upon request.
Please e-mail connect@seattlebiomed.org.
Statements of nancial position
2012 2011
Cash & investments $19,867,435 $21,203,046
Pledges receivable $263,797 $3,484,055
Other assets $7,719,694 $7,683,610
Property & equipment $9,488,075 $10,170,785
Total assets $37,339,001 $42,541,496
Accounts payable & accrued expenses $6,932,498 $4,704,532
Advances & deferred obligations $8,070,453 $10,335,651
Capital project debt $1,059,932 $2,608,351
Total liabilities $16,062,883 $17,648,534
Total net assets $21,276,118 $24,892,962
Statements of activities
2012 2011
Support & revenue
Government grants $31,430,061 $27,858,893
Private grants $11,606,758 $12,599,217
Contributions $558,259 $7,621,585*
Educational program $81,405 $99,442
Investment & other income $3,037,115 $3,394,990
Total support & revenue $46,713,598 $51,574,127
Expenses
Research program $42,778,277 $38,947,458
Educational program $594,243 $869,233
Management & administrative $6,549,447 $6,080,604
Fundraising $408,474 $729,667
Total expenses $50,330,441 $46,626,962
Increase (decrease) in net assets ($3,616,843) $4,947,165
Revenue & support
2012
Contributions 1%
Other income 6%
Government
Grants 69%
Private
Grants 24%
Budget by program area
HIV/AIDS
33%
Emerging
& Neglected
Diseases 29%
Malaria 32%
Tuberculosis 6%
2012
2012 HONOR ROLL
Thank you for your support.
The 2012 donor list includes new pledges, outright gifts of cash and stock, pledge payments, and in-kind donations received
from July 1, 2011, through June 30, 2012. Donors of $1,000 and above are listed on the donor wall at Seattle BioMed.
Each of our donors is important to us. Please e-mail connect@seattlebiomed.org with any omissions or errors.
14 13
$1,000,000+
Bill & Melinda Gates Foundation
James B. Pendleton Charitable Trust
$50,000+
Dean & Vicki Allen/McKinstry Co.
Charitable Foundation
Washington State Department of Agriculture
$25,000+
Byron & Alice Lockwood Foundation
Gilbert Scherer & Marlyn Friedlander
$10,000+
Drs. Alan Aderem & Kathy Barker
Anonymous (2)
Charles Spear Charitable Trust
The Crystal Family Foundation
James & Sarah Davie
Richard & Elizabeth Hedreen
KeyBank Foundation
Todd & Julie Patrick
Gloria Pfeif
Judy Pigott
Becky Roberts
The Team Trio Fund In Honor & Remembrance
of Dr. David Clemetson
$5,000+
Perry, Christine, & Cooper Atkins
Gregg & Jane Blodgett
Maud & Marc Daudon
David & Amy Fulton
Gilead Sciences, Inc.
Racha & Wassef Haroun
Jane Hedreen & David Thyer
Mike & Liz Hilton
KeyBank National Association
Kinzer Real Estate Services
Lease Crutcher Lewis
Petrizzo Bond, Inc.
Gordon & Gretchen Raine
Lucie Robitaille & Antoine Leblond
Ronald & Sara Seubert
Drs. Ken Stuart & Julie McElrath
Mike & Sandra Stull
Vulcan Inc.
Wells Fargo Insurance Services
Melissa Yeager & Cory Van Arsdale
$2,500+
Dr. John & Leslie Aitchison
Alexandria Real Estate Equities Inc.
Mark Ashida & Lisbet Nilson
ATS Automation
The Baden Family
Drs. Jane A. Biddle & Kenneth B. Seamon
BioMed Realty Trust, Inc.
Betty Bottler
Bristol-Myers Squibb Co.
Susan P. Brown
Bullitt Foundation
Concur Technologies, Inc.
Firland Foundation
GLY Construction
Group Health Cooperative
Betsy & Eric Hentz
Jones Lang LaSalle
Leroy Hood
Mark Malamud & Susan Hautala
Trevor J. Moody & Laura Hernon
Moss Adams LLP
NBBJ
Christopher & Kathryn Porter
Kris Richey Curtis
Sabey Corporation
Salal Credit Union
Daniel D. Syrdal
Kristin Tolle, Ph.D.
Moya Vazquez
VLST Corporation
Jeanine Willis & Eric Freyberg
Debra Wilson
$1,000+
Anonymous (4)
Kevin & Patrice Auld
Richard Bear
Bonnie Berk
Steve & Marijo Brantner
David Brenner
Clark Nuber P.S.
Paul & Debbie Cressman
Earl & Anita Davie
Patrick Duffy
Renee Duprel
Carolynn & Hal Ferris
JoAnn & Barry Forman
Greg Foster
M. Elizabeth Halloran
Randy & Melanie Hassler
Lee & Ginnie Huntsman
Darryl & Kathleen Johnson
Pam & Kim Kaiser
Margot Kenly & Bill Cumming
Jim Ladd
Maureen Lee & Mark Busto
Life Technologies
Dori McLennan
Peter Miller & Jean Johnson
Morningside Foundation
Shirley Naganawa & Gary Kawasaki
Charles & Eleanor Nolan
PATH
Perkins Coie
Anne Pfeif
Judith Pierce
William & Jennifer Pollard
Chris & Julie Prentice
Wendy & Bill Rabel
Regina Rabinovich & Franco Piazza
Redman Family Foundation
The Reuben B. Robertson Foundation
James & Joy Roush
Christine Simon
Chris & Aniko Somogyi
Leo Stamatatos & Tina de Jong
Margaret & Hunt Stockwell
Bob & Katie Strong
Steven & Karen Van Til
Doug & Stacey Waddell
Waldron
Mariann & Kirk Zylstra
$500+
The Aitchison Lab
Anonymous (3)
Rosemary Barker Aragon & Luis Aragon
Nitin Baliga, Ph.D. & Janet Cebbalos
John & Tricia Bencich
Karen Blchlinger
Sissy Bouchard, Ed.D. & Tom Bouchard, Ph.D.
Hal Breier
Robert & Theresa Britschgi
Tom & Claudia Campanile
John W. Creighton III
Dr. and Mr. Dirac
Jennifer Dodson
Beth & Marc Droppert
Robert & Deborah Fleming
Kerry Fowler & Jan Gray
Rachel & Paul Freed
Malcolm J. Gardner & Ruobing Wang
Ted and Barbara Gauld
Robyn & Philip Grad
Hamilton Hazlehurst & Pam Bekins
Helen Horton & Donald Carter
Drew & Alison House
Kent & Louise Irwin
J & C Voyageurs Ltd.
Allegra Johnson
R. Hans & Kelly Kemp
Maryann Jordan & Joe McDonnell
Christopher Karp
ChiEun Kim
Michael Kreis & Cathryn Vandenbrink
Laird Norton Company LLC
Peter & Melba Lancaster
Don & Carla Lewis
Terry Meersman & Carmen de la Hoz
Michael & Julie Metzger
Susan & Isaac Morgensztern
Peter Myler & Alexa Allen
Robert & Carol Odem
Geoff & Kathy Osler
Marilyn Parsons
Lindsey & Justin Patrick
Patricia Pfeif
Prairie Foundation
Audi Purnaveja
Erick & Marta Rabins & Family
Robert L. & Virginia R. Rausch
Chris Rivera
Scott & Kerry Rosenkranz
SABArchitects, Inc.
Will & Lee Schoentrup
Sellen Construction
Drs. David Sherman & Jeanette Farrell
Haeryung Shin & Andrew von Nordenycht
Kristin Stred & Terry Prether
Sandhya Subramanian, Steve Seitz
Kate Tune
Tad Whiteside
Ann P. Wyckoff
Jane Zalutsky & Mark Kantor
$250+
Lynn Amon and Ed Kromer
Anonymous
Matt Arentz
Cameron Bays
Kristin & Steven Beaulieu
Jeanne Brovold
Larry T. & Maggie S. Burke
Clete & Bronwen Casper
Betty Chandler
Nick Crispe, Ph.D.
Joshua Curtis
Mark & Deb Davis
Barclay Dean
Ken Duncan
Barbara Fielden
Christoph Grundner
Sierra Hansen & Barbara Wilson
Kitty Harmon
Joe & Denise Harris
Richard Harris
Herd Freed Hartz
Toni Hatzakis
Leslie Helm & Marie Anchordoguy
Rafael Hernandez
Gordon Hofman
Arthur E. Holtz
Katy Horan & Dan Filonowich in honor
of Heath Fox & Julie Richman
David C. Howland
Elizabeth James
Gail James
Irene & Timothy Kilgallon
Joseph King & Whitney McCleary
Alvin & Verla Kwiram
Alan & Sharon Levy
Kim Loveall Price
Loveall Price & Associates LLC
The Madden Family
George & Beverly Martin
McGraw-Hill
Tracy Mitchell
Bob & Nicole Mooney
Joanne & Bruce Montgomery, M.D.
Peggy Morrow
Eileen & Barry Murphy
Alex Nachman
David & Julie Park
David Poston
Sally Quy
Maria K. Reyes
Dr. Mack & Susan Richey
Steve & Charlotte Roberts
Mike Ruhl
Russell Investments Matching Gifts Program
Paul & Robin Schachter
Sidiya Schoppert
Genie Sheth
Barbara A. Shickich
Jeff Shober & Deb Nalty, M.D.
Joseph & Leia Smith
Don Sodora
Jay Sorensen
David & Lucinda Stewart
Erik Strom
Michael Swift
Jasna H. Trnka
James Tucker
David Tutt
Dr. Maria Vasilakis
Washington Biotechnology &
Biomedical Association
Peter I. Way
Brandon Weber
Katherine Weybright
Ron Wilkowski & Kyla Fairchild
You hold the key to our acceleration.
The people with the most inuence on global health are people like you. You have
invested your time and money, and you have joined us on our journey to end the threat
of infectious disease. Individuals, foundations and corporations that imagine a world free
from this burden play a signicant role in enabling Seattle BioMed to expand research
programs, recruit innovative scientists and form powerful collaborations that will ultimately
lead to a healthier world.
Mission
Every day, we strive to eliminate the worlds most
devastating infectious diseases.
Vision
We envision a world where people live free from the
threat of infectious disease.
About Seattle BioMed
Seattle BioMed is the largest, independent, non-prot
research institute in the U.S. focused solely on the worlds
most devastating infectious diseases. More than 330
strong, we are dedicated to reducing human suffering
and saving lives by converting knowledge into solutions.
Our research is the foundation for new vaccines, drugs
and diagnostics that will benet those who need our
help most: the 14 million who will otherwise die each
year from infectious diseases.
Disease Focus
Emerging & Neglected Diseases
African sleeping sickness
Amebiasis
Chagas disease
Leishmaniasis
Toxoplasmosis
Malaria
Tuberculosis
Viral Diseases
HIV/AIDS
Inuenza

Printed on recycled paper.
2013 Seattle Biomedical Research Institute.
307 Westlake Avenue North, Suite 500 Seattle, Washington 98109-5219 USA
Phone: 206.256.7200 Fax: 206.256.7229 - seattlebiomed.org
2012
Freedom from Infectious Disease
ANNUAL REPORT
Seattle Biomedical Research Institute is a 501(c)3 nonprot organization.
Federal tax ID #91-0961784.
Accelerating Progress Help us continue to accelerate.